ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
2.4750
+0.1650 (+7.14%)
At close: 12:53PM EDT
Stock chart is not supported by your current browser
Previous Close2.3100
Open2.3000
Bid2.3500 x 1000
Ask2.8000 x 800
Day's Range2.3000 - 2.4750
52 Week Range2.3000 - 8.4850
Volume1,175
Avg. Volume18,118
Market Cap65.657M
Beta (3Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-1.0450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.75
Trade prices are not sourced from all markets
  • GlobeNewswire

    ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    SINGAPORE, Aug. 13, 2019 -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results.

  • GlobeNewswire

    ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on varlitinib has been accepted for poster presentation at the upcoming 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain on 27 September - 1 October 2019. ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors” will be presented by Dr. Aaron Tan. Varlitinib is a highly potent pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4.

  • GlobeNewswire

    ASLAN Pharmaceuticals Names Industry Veteran and Current Board Member Andrew Howden to Additional Role of Chairman

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that Andrew Howden has been elected as non-executive Chairman of the Board. Dr Carl Firth, who has held the positions of Chairman and CEO since founding the company in 2010, will continue to serve as CEO and as a Director. Andrew Howden has served as a member of ASLAN’s board of directors since April 2016 and brings over 35 years of commercial and leadership experience in the pharmaceutical industry.

  • ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
    Zacks

    ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

    ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the successful completion of its single ascending dose (SAD) study testing the first-in-class therapeutic antibody ASLAN004 in healthy volunteers, and the updated data from the second part of the study that tested a subcutaneous formulation of ASLAN004. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signalling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis (AD), such as redness and itching of the skin. Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals, said: “The final data from the phase 1 study reaffirms our belief that ASLAN004 has the potential to be a best-in-class therapy for atopic dermatitis and allows us to quickly move into a multiple ascending dose study later this year.

  • GlobeNewswire

    ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has amended its license agreement with CSL Limited (CSL) so that ASLAN has full global rights to develop, manufacture and commercialise ASLAN004 in all indications. The amended agreement replaces the licensing agreement ASLAN and CSL signed in May 2014. Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals, said: “We are very excited by the recent data we have generated on ASLAN004 and we believe that it has the potential to be a best-in-class treatment for atopic dermatitis and other inflammatory indications with a differentiated profile.

  • GlobeNewswire

    ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has signed an agreement with the Korean Cancer Diagnosis & Treatment Enterprise (K-MASTER) to investigate varlitinib in a phase 1b/2 multi-centre umbrella study to evaluate the safety and efficacy of varlitinib in combination with weekly paclitaxel as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients. K-MASTER, operated by Korea University, is funded by the South Korean government to support three key goals: genomic sequencing of cancers, clinical trials for South Korean cancer patients, and the development of a cancer genomics database. K-MASTER is already involved in 16 clinical trials, which include testing new drugs targeted at specific cancer mutations.

  • ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why
    Zacks

    ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why

    ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

    SINGAPORE, April 29, 2019 -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical stage oncology and immunology focused biopharmaceutical company developing novel.

  • Top Ranked Momentum Stocks to Buy for March 29th
    Zacks

    Top Ranked Momentum Stocks to Buy for March 29th

    Top Ranked Momentum Stocks to Buy for March 29th

  • GlobeNewswire

    ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company developing novel therapeutics for global markets, today announced the completion of the first part of the single ascending dose (SAD) study testing the intravenous formulation of the first-in-class therapeutic antibody ASLAN004 in healthy volunteers. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signalling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin.

  • Top Ranked Momentum Stocks to Buy for March 28th
    Zacks

    Top Ranked Momentum Stocks to Buy for March 28th

    Top Ranked Momentum Stocks to Buy for March 28th

  • GlobeNewswire

    ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    SINGAPORE, March 22, 2019 -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for.

  • GlobeNewswire

    ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, and BioGenetics Co Ltd, a leading South Korean healthcare company, have expanded their strategic collaboration by entering into a new commercialisation agreement whereby both parties will partner to commercialise ASLAN003 in all indications in South Korea. ASLAN will grant BioGenetics exclusive rights to commercialise ASLAN003 in South Korea in exchange for an upfront payment of US$1 million and up to US$8 million in sales and development milestones. ASLAN is also eligible to receive tiered double digit royalties on net sales from the high-teens to the mid-twenties range.

  • GlobeNewswire

    ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, and BioGenetics Co Ltd, a leading South Korean healthcare company, have entered into an agreement whereby both parties will collaborate to commercialise varlitinib in all indications in South Korea. ASLAN will grant BioGenetics exclusive rights to commercialise varlitinib in South Korea in exchange for an upfront payment of US$2 million and up to US$11 million in sales and development milestones. ASLAN is also eligible to receive tiered double digit royalties on net sales up to the mid-twenties.

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today announced a strategic corporate restructuring to focus its resources on its lead clinical programs: varlitinib in biliary tract cancer (BTC), ASLAN003 in acute myeloid leukaemia (AML) and ASLAN004 in atopic dermatitis. ASLAN will focus its resources on the late-stage development of varlitinib as a potential novel treatment for first- and second-line BTC. Enrolment in a global pivotal study of varlitinib in second-line BTC, the TreeTopp (TREatmEnT OPPortunity) study, was completed ahead of schedule in December 2018 and topline data is expected in the second half of 2019.

  • GlobeNewswire

    ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that new pre-clinical data on varlitinib’s activity in triple negative breast cancer (TNBC) cell lines have been published online in Cancers, a peer-reviewed oncology journal. The data suggest that HER-family signalling plays an important role in TNBC progression and that pan-HER inhibition is potentially an effective treatment for TNBC patients. The article titled “Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells” details the findings of the pre-clinical study in which investigators evaluated the efficacy of varlitinib, a reversible small molecule pan-HER inhibitor, in TNBC.

  • GlobeNewswire

    ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced positive data from an ongoing multicentre phase 1b/2 clinical trial (ASLAN001-007) of varlitinib plus gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC). Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “The responses we have seen with varlitinib in this clinical trial are impressive, especially when compared to historical data for the current standard of care, gem/cis for biliary tract cancer. Apart from combination chemotherapy, no progress has been made in the development of new treatment options for BTC patients.

  • ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
    Zacks

    ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

    ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update on its global placebo-controlled, double-blind phase 2 clinical study of varlitinib as a first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients, comparing varlitinib plus mFOLFOX6 to placebo plus mFOLFOX6. To date, no targeted therapies have been approved to treat gastric cancer with low HER-family expression.

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug (IND) application for ASLAN003. The company plans to evaluate ASLAN003 in the United States as part of an ongoing Phase 2 clinical trial. ASLAN003 is a potential treatment for acute myeloid leukaemia (AML), for which the FDA has previously granted Orphan Drug Designation.

  • GlobeNewswire

    ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of patient enrolment in TreeTopp (TREatmEnT OPPortunity), a global pivotal study investigating varlitinib in second-line biliary tract cancer (BTC). It is the largest global, placebo-controlled study in BTC conducted to date. The study recruited 127 patients who have failed first line therapy from 56 sites worldwide including the US, Europe, Australia, Japan, Korea and other Asia Pacific countries.

  • GlobeNewswire

    New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new positive data from the ongoing phase 2a study of ASLAN003 for the treatment of acute myeloid leukaemia (AML) at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, US. ASLAN003 is an orally active, potent inhibitor of dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in AML. As of 16 November 2018, 14 patients with AML ineligible for standard treatment (including relapsed, refractory and treatment naïve) had been enrolled in the multicentre dose optimisation study to evaluate ASLAN003 monotherapy administered as a 28-day cycle.

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium

    SINGAPORE, Nov. 27, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.